News
CORT
22.21
-1.20%
-0.27
Corcept Therapeutics to Announce First Quarter Financial Results, Provide Corporate Update and Host Conference Call
Corcept Therapeutics Incorporated will report first quarter financial results and provide a corporate update on May 1, 2024. The company will also host a conference call that day. Corcept will report the results on a fiscal year ending April 30, 2024, in California.
Barchart · 1d ago
Corcept Therapeutics Price Target Maintained With a $38.00/Share by HC Wainwright & Co.
Dow Jones · 2d ago
HC Wainwright & Co. Reiterates Buy on Corcept Therapeutics, Maintains $38 Price Target
Benzinga · 2d ago
Corcept (CORT) Posts Positive Data From Cushing's Syndrome Study
NASDAQ · 2d ago
Promising Clinical Outcomes and Market Potential: Buy Rating for Corcept’s Relacorilant
TipRanks · 2d ago
20 companies screened for quality in a cheap part of the stock market
MarketWatch · 2d ago
Analysts Are Bullish on These Healthcare Stocks: Corcept Therapeutics (CORT), Structure Therapeutics, Inc. Sponsored ADR (GPCR)
TipRanks · 2d ago
Notable Monday Option Activity: RIOT, SIG, CORT
NASDAQ · 3d ago
BUZZ-U.S. STOCKS ON THE MOVE-AZZ, Vanda Pharma, Matterport
U.S. Stocks rose on Monday in choppy trading. The Dow Jones Industrial Average was up 1.01% at 38,371.51. The top three S&P 500 percentage gainers were Ford Motor Co, Nvidia and Vanda Pharma. The market is looking ahead to major tech earnings and a key inflation print this week. AZZ, Vanda Pharmaceutical and Matterport are up on the day.
Reuters · 3d ago
Mid-Cap Corcept Therapeutics Reveals Data From Hormonal Disorder Study, FDA Application Submission Expected This Quarter
Corcept Therapeutics releases results from the open-label portion of the pivotal Phase 3 GRACE trial of its cortisol modulator relacorilant. The drug is being tested in patients with Cushing’s syndrome and hypertension. The study showed rapid and sustained improvements in blood pressure and glucose metabolism.
Benzinga · 3d ago
BUZZ-U.S. STOCKS ON THE MOVE-AZZ, Smartsheet, Zions Bancorporation
Wall Street's main indexes rose on Monday after steep losses in the previous session. The Dow Jones Industrial Average was up 0.31% at 38,103.16. The top three S&P 500 percentage gainers were Ford Motor Co, Nvidia and Zions Bancorporation. Major tech earnings and a key inflation print are on the agenda this week.
Reuters · 3d ago
Corcept falls after phase 3 results on Cushing's candidate doesn't include some data
Corcept falls after phase 3 results on Cushing's candidate doesn't include some data. Corcept Therapeutics is off 3% in Monday morning trading. The company reported positive results from a phase 3 trial of a Cushings's syndrome candidate. But it didn't provide data from the placebo-controlled portion of the trial.
Seeking Alpha · 3d ago
BUZZ-Corcept falls on limited data from late-stage trial of Cushing's syndrome drug
Corcept falls on limited data from late-stage trial of Cushing's syndrome drug. Shares of Corcept Therapeutics fall 4.4% to $21.93. Company says drug relacorilant showed statistically significant improvements in high blood pressure and blood sugar levels.
Reuters · 3d ago
Weekly Report: what happened at CORT last week (0415-0419)?
Weekly Report · 3d ago
CORCEPT THERAPEUTICS: STATISTICALLY SIGNIFICANT IMPROVEMENTS IN HYPERTENSION, HYPERGLYCEMIA AND OTHER KEY SECONDARY AND EXPLORATORY ENDPOINTS
Reuters · 3d ago
CORCEPT THERAPEUTICS INC: NO CASES OF RELACORILANT-INDUCED ENDOMETRIAL HYPERTROPHY WITH OR WITHOUT VAGINAL BLEEDING WERE SEEN
Reuters · 3d ago
CORCEPT THERAPEUTICS INC: RELACORILANT WAS WELL TOLERATED
Reuters · 3d ago
Corcept (CORT) Upgraded to Strong Buy: Here's What You Should Know
NASDAQ · 04/17 16:00
New Strong Buy Stocks for April 17th
NASDAQ · 04/17 11:26
Corcept (CORT) Completes Enrollment in Phase II ALS Study
NASDAQ · 04/16 15:34
More
Webull provides a variety of real-time CORT stock news. You can receive the latest news about Corcept Therapeutics Inc through multiple platforms. This information may help you make smarter investment decisions.
About CORT
Corcept Therapeutics Incorporated is a commercial-stage company, which is engaged in the discovery and development of medications to treat severe endocrine, oncologic, metabolic and neurological disorders by modulating the effects of the hormone cortisol. The Company operates through the discovery, development and commercialization of the pharmaceutical products segment. The Company has marketed Korlym (mifepristone) in the United States for the treatment of patients suffering from Cushings syndrome. The Company’s portfolio of selective cortisol modulators consists of four series totaling approximately 1,000 compounds. Its portfolio of selective cortisol modulators consists of relacorilant, exicorilant, dazucorilant and miricorilant. Korlyms active ingredient, mifepristone, reduces the binding of excess cortisol to the GR, it can modulate the effects of abnormal levels and release patterns of cortisol without compromising cortisols healthy functions and rhythms.